Table 3

Drug Therapies and Endothelial Progenitor Cells

StudyPatientsTherapyEffects on EPC NumberEffect on EPC Function
Llevadot et al. (65)NDSimvastatin↑Proliferation↑Migration
Dimmeler et al. (66)HealthySimvastatin, mevastatin, atorvastatin↑ProliferationND
Vasa et al. (70)CADAtorvastatin↑EPC number↑Migration
Assmus et al. (12)HealthyAtorvastatin↑Proliferation↓Senescence
MevastatinNE↓Senescence
Walter et al. (69)NDSimvastatinND↑Adhesion
Spyridopoulos et al. (71)HealthyAtorvastatin, mevastatinND↑Migration
Landmesser et al. (72)Heart failureAtorvastatin, ezetimibe↑In culture NEND
Bahlmann et al. (73)Diabetes melitusOlmesartan, irbesartan↑In cultureND
Imanishi et al. (32)HealthyValsartanND↓Senescence
Min et al. (74)CADRamipril↑In culture↑Proliferation, migration, adhesion, in vitro vasculogenic capacity
Bahlmann et al. (83)Renal anemia, healthyErythropoietin↑Circulating CD34+/CD45+cells, ↑in culture↑In vitro vasculogenic capacity
Heeschen et al. (81)CADErythropoietin levelsCorrelate with EPC numberCorrelate with migration capacity
Pistrosch et al. (38)DiabetesRosiglitazone↑In culture↑Migration
Foresta et al. (77)HealthyVardenafil↑Circulating EPCsND
Zhu et al. (78)NDPuerarin↑In culture↑Migration, adhesion, in vitro vasculogenic capacity
Chen et al. (79)NDGinkgo biloba↑In culture↑Migration, adhesion, in vitro vasculogenic capacity
Butzal et al. (80)NDRapamycin↓In culture↓Differentiation, adhesion, ↑apoptosis

Abbreviations as in Table 1.